louisbrulenaudet/clinical-trials huggingface dataset:
Clinical trial NCT04063735: Alleviating Effects Against Dry Eye by Oral Intake of Cordyceps Cicadae Mycelia
Official title: Alleviating Effects Against Dry Eye by Oral Intake of Cordyceps Cicadae Mycelia
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Dry Eye
Supplement
Keywords: Dry Eye
Cordyceps cicadae mycelia
Lead sponsor: Chung Shan Medical University
Sponsor class: OTHER
Collaborators: name: Grape King Bio Ltd.
First posted: 2019-08-21
Enrollment: 97
Sex: ALL
Minimum age (years): 20
Maximum age (years): 60
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Intervention model description: Randomized double-blinded placebo study
Primary purpose: OTHER

Brief summary: Cordyceps cicadae mycelia was tested for amelioration of dry eye symptoms through dietary supplementation. Its efficacy in relief of human dry eye status was assessed by randomized, double-blinded tests, including multiple assessments. The results were compared between the placebo group and the experimental group.

Detailed description: Former animal studies had shown that Cordyceps cicadae mycelia can effectively ameliorate UVB-induced dry eye symptoms. This study further investigated its efficacy in human dry eye status by randomized, double-blinded tests, including dry eye questionnaires, blood tests, salivary tests, tear volume test, intra-ocular pressure assessments, ocular surface photography, corneal fluorescein stain, tear film breakup time test, fundus photography, and cornea impression cytology. All tests were performed again after 3 months of dietary supplement of either samples or placebo. A total of 97 participants completed the trial. The data were analyzed by paired-t test and compared between the placebo and the experimental groups.

Eligibility criteria: Inclusion Criteria:

* Adults aged from 20 to 60 with dry eye symptoms confirmed by ophthalmologists, and without chronic diseases.

Exclusion Criteria:

* Those vulnerable to damages or loss of self-conscious, or behavior capacity, or with major illness or with critical diseases.

Primary outcomes:
measure: tear film breakup time
timeFrame: day 1 to day 90.
measure: Cornea surface scores based on Efron grading system
timeFrame: day 1 to day 90.
measure: Intra-ocular pressure
timeFrame: day 1 to day 90.
Secondary outcomes:
Other outcomes:
Locations:
Study officials:
affiliation: Chung Shan Medical University
name: David Pei-Cheng Lin, PhD
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT03140735: Interest of Pulse Wave Velocity Measurement as a Predictor of Severity of Aortic Stenosis
Official title: Interest of Pulse Wave Velocity Measurement as a Predictor of Severity of Aortic Stenosis
Study type: INTERVENTIONAL
Overall status: WITHDRAWN
Phase: NA
Conditions: Pulse Wave
Aortic Stenosis
Lead sponsor: Centre Hospitalier Universitaire, Amiens
Sponsor class: OTHER
First posted: 2017-05-04
Enrollment: 0
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NON_RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: Aortic valve pathology is the third most common cardiovascular disease after coronary artery disease and hypertension, which is responsible for severe morbidity and mortality in elderly patients and requires surgical treatment in its most severe form of progression. The purpose of this study is to find a link between arterial stiffness and degenerative aortic stenosis. If this link is established, arterial stiffness may become a medical therapeutic target in order to delay the evolution of the disease.


Eligibility criteria: Inclusion Criteria:

* Patients over 18 years of age, without legal protection (guardianship or curatorship),
* Stable hemodynamic status.
* Affiliation to a social security scheme

Exclusion Criteria:

* Hemodynamically unstable patients: Systolic PA \<10 cmHg, rapid peripheral pulse and spinning, mottling, obnubilation, oliguria, sweating, coma
* History of significant valvulopathy other than an aortic stenosis,
* Pregnancy.
* Patient under tutelage or curatelle or deprived of public right.

Primary outcomes:
measure: Analysis of echocardiographic measurements of possible differences between average VOP and Sao i in terms of RA severities
timeFrame: 10 years
Secondary outcomes:
Other outcomes:
Locations:
city: Amiens
country: France
facility: CHU Amiens Picardie
state: Picardie
Study officials:
References:
Clinical trial NCT06631235: Comparison Between Aesthetic Functional Appliances and Twin Block in Correction of Skeletal Class II
Official title: Comparison Between Aesthetic Functional Appliances and Twin Block in Correction of Skeletal Class II: Randomized Controlled Study
Study type: INTERVENTIONAL
Overall status: NOT_YET_RECRUITING
Phase: NA
Conditions: Skeletal Malocclusion
Keywords: classII
mandibular advancement
twin block
Lead sponsor: Mansoura University
Sponsor class: OTHER
First posted: 2024-10-08
Enrollment: 42
Sex: ALL
Minimum age (years): 8
Maximum age (years): 12
Standard ages: CHILD
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: The goal of this is to evaluate the skeletal, dental and soft tissue effects between aesthetic functional appliance and Twin block appliance in treatment of skeletal class II in ( growing male/female patients)

Detailed description: The sample will be randomly divided into 2 equal groups according to the appliance will be used:

Group 1: Aesthetic Functional appliance Group 2: Twin block

Methods:

\*Radiographs (CBCT) will be taken before starting the treatment (T1) and after obtaining Class I occlusion and normal overjet (T2) by sequential appliances.

appliances.

* Lateral cephalograms -extracted from CBCT- will be used to evaluate the effect of the two appliances.
* CBCT will be used to evaluate root resorption and bony changes in the condyle .

Eligibility criteria: Inclusion Criteria:

* Skeletal Class II pattern with ANB angle exceeding 6° and Wits appraisal of 2 mm or more.
* Mandibular deficiency (SNB angle less than 77°).
* Growing patients.
* No prior orthodontic intervention.
* The vertical skeletal classification shows a horizontal or neutral growth pattern.
* Overjet ≥ 8mm.

Exclusion Criteria:

* Developmental abnormalities with atypical or irregular patterns of growth and maturation.
* Any indications or manifestations, as well as any prior medical records, of Tempro-Mandibular Joint (TMJ) disorders, such as the presence of clicking, pain, limitations, or deviations.

Primary outcomes:
measure: skeletal effects
timeFrame: one year
measure: dental effects
timeFrame: one year
measure: soft tissue effects
timeFrame: one year
Secondary outcomes:
measure: root resorption
timeFrame: one year
Other outcomes:
measure: CBCT evaluation of TMJ
timeFrame: one year
Locations:
city: Mansoura
country: Egypt
facility: Faculty of Dentistry
state: Dakahlia
Study officials:
affiliation: Egyption orthodontic socity
name: rana ka Abuzaid, orthodontist
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT04839835: Anxiety on the First Day of Chemotherapy
Official title: The Effect of Art Design in the Chemotherapy Waiting Room on the Anxiety of Patients Who Will Receive Chemotherapy for the First Time
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Breast Cancer
Anxiety
Lead sponsor: Namik Kemal University
Sponsor class: OTHER
First posted: 2021-04-09
Enrollment: 106
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 99
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: OTHER

Brief summary: investigating chemotherapy anxieties

Detailed description: Breast cancer is the most common type of cancer in women in the world, and it is the first in cancer-related deaths in women all over the world. In the treatment of breast cancer, in addition to surgery, patients with advanced stage or high risk of recurrence receive neoadjuvant and adjuvant chemotherapy treatments. This period starts with 3 months and extends according to the treatment protocols it will receive.

Since the first diagnosis of breast cancer, it has psychological effects such as intense stress, decrease in quality of life and anxiety as well as physical effects on patients. The time spent in the "waiting room" while patients are examined and receiving treatment before chemotherapy inevitably has an effect on their anxiety.

In this study; It was aimed to investigate the effects of environmental factors in waiting rooms on patients' anxiety.

Eligibility criteria: Inclusion Criteria:

* to receive chemotherapy for breast cancer for the first time
* give consent for the study

Exclusion Criteria:

* not approving to participate in the study

Primary outcomes:
measure: anxiety and stress measurements
timeFrame: 60-120 minutes
Secondary outcomes:
Other outcomes:
Locations:
city: Tekirdağ
country: Turkey
facility: Tekirdağ Namık Kemal ÜNiversitesi
Study officials:
References:
Clinical trial NCT06051435: Effect of Lumbar Proprioception Training on Primary Dysmenorrhea
Official title: Effect of Lumbar Proprioception Training on Primary Dysmenorrhea: A Randomized Clinical Trial
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: NA
Conditions: Primary Dysmenorrhea
Keywords: lumbar proprioception training
pelvic rocking exercises
primary dysmenorrhea
Lead sponsor: Cairo University
Sponsor class: OTHER
First posted: 2023-09-22
Enrollment: 30
Sex: FEMALE
Minimum age (years): 18
Maximum age (years): 22
Standard ages: ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: the aim of this study will be to investigate the effect of lumbar proprioception training on primary dysmenorrhea.

Detailed description: Although previous studies reported the effect of physiotherapy practices through therapeutic exercises on primary dysmenorrhea as core muscles strengthening, core stability exercises, connective tissue massage and classical massage, relaxation, strengthening, stretching, aerobic exercises, pelvic floor muscle strengthening exercises, yoga and Pilates. None of them have investigated the effect of lumbar proprioception training on primary dysmenorrhea. Therefore, this study will be the first one which aims to investigate the effect of lumbar proprioception training on primary dysmenorrhea. This trial will include 2 groups; group A composed of 20 females that will receive hot packs and pelvic rocking exercises for 4 weeks and group B also composed of 20 females that will receive hot packs and pelvic rocking exercises in addition to lumbar proprioception training for 4 weeks.

Eligibility criteria: Inclusion Criteria:

* All females will have moderate to severe primary dysmenorrhea (as determined by WaLIDD Scale).
* Their ages will range from 18 to 22 years old.
* All females will be virginal and non-smokers.
* Their BMI will be range from 20-25 kg/m2
* They have regular menstrual cycle with menstrual cycle length of 28-30 days.
* They have persistent primary dysmenorrhea of more than 6 months

Exclusion Criteria:

* They shouldn't have musculoskeletal or neurological disorders, chronic LBP or sacroiliac dysfunction, diabetes, pelvic pathology or any gynecological disease.
* They shouldn't experience a stressful event in the last 6 month.
* Attending regular exercise training in the last 6 months.
* Taking medications or vitamin and mineral supplements due to other medical conditions.

Primary outcomes:
measure: Measurement of lumbar proprioception
timeFrame: 4 weeks
Secondary outcomes:
measure: Calculation of score of WaLIDD Scale
timeFrame: 4 weeks
measure: lumbar curvature angle
timeFrame: 4 weeks
Other outcomes:
Locations:
city: Giza
country: Egypt
facility: Doaa Osman
Study officials:
affiliation: Professor, Cairo university
name: Amel Mohamed Yousef, PhD
role: STUDY_CHAIR
affiliation: Assistant Professor, Cairo university
name: Hamada Ahmed Hamada, PhD
role: STUDY_DIRECTOR
References:
Clinical trial NCT04470635: Thiol/Disulphide Homeostasis and Vascular Endothelial Growth Factor Levels in Diabetic Children
Official title: Thiol/Disulphide Homeostasis and Salivary Vascular Endothelial Growth Factor Levels in Type 1 Diabetic Patients With Gingivitis
Study type: OBSERVATIONAL
Overall status: COMPLETED
Conditions: Periodontal Diseases
Keywords: type 1 diabetes mellitus
Lead sponsor: Aydin Adnan Menderes University
Sponsor class: OTHER
First posted: 2020-07-14
Enrollment: 80
Sex: ALL
Minimum age (years): 7
Maximum age (years): 14
Standard ages: CHILD
Observational model: CASE_CONTROL
Time perspective: PROSPECTIVE
Sampling method: PROBABILITY_SAMPLE
Study population: Eigthy children will be recuited for the study . The children will be classified into four subgroups based on their periodontal status;

1) systemically and periodontally healthy children, 2) systemically healthy children with gingivitis (G), 3) periodontally healthy children with T1DM, and 4) children with T1DM and gingivitis . The plaque index, gingival index and probing pocket depth will be recorded. The vascular endothelial growth factor in saliva will be determined by ELISA. Additionally total and native thiao and disulphide levels in saliva will be determined.

Brief summary: The aim of this study to evaluate the vascular endothelial growth factor level and thiol/disulphide homeostasis in saliva of diabetic children with gingivitis.

Detailed description: Eighty children (44 with type 1 diabetes mellitus and 44 systemically healthy) will be recruited for the study. The children will be divided into four subgroups based on their periodontal and systemic condition: 1) systemically and periodontally healthy children, 2) systemically healthy children with gingivitis, 3) periodontally healthy children with T1DM, and 4) children with T1DM and gingivitis. The plaque index, gingival index, probing pocket depth, will recorded. The vascular endothelial growth factor level determined by ELISA. Native thiol, total thiol and disulphide levels will be measured in saliva.

Eligibility criteria: Inclusion Criteria:

* Children diagnosed as type 1 diabetes mellitus
* Age between 7-14 years

Exclusion Criteria:

* Having another systemic problem except type 1 diabetes mellitus
* Children carrying orthodontic appliances

Primary outcomes:
measure: Vascular endothelial growth factor level
timeFrame: Baseline
Secondary outcomes:
measure: Thiol/disulphide measurement
timeFrame: Baseline
Other outcomes:
Locations:
city: Aydın
country: Turkey
facility: Sultan Keles
Study officials:
affiliation: Aydin Adnan Menderes University
name: Sultan KELES, Assoc.Prof.
role: PRINCIPAL_INVESTIGATOR
References:
Clinical trial NCT00227435: Dose Escalation Study to Evaluate the Safety and Antiviral Activity of Val-mCyd in Adults With Chronic Hepatitis C
Official title: A Phase I/II Double-Blind, Dose Escalation Study to Evaluate the Safety, Pharmacokinetics and Antiviral Activity of Val-mCyd (NM283) in Adults With Chronic Hepatitis C
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Chronic Hepatitis C
Lead sponsor: Merck Sharp & Dohme LLC
Sponsor class: INDUSTRY
First posted: 2005-09-28
Sex: ALL
Minimum age (years): 18
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: TREATMENT

Brief summary: This study was conducted to determine the safety, tolerance, pharmacokinetics and antiviral activity of val-mCyd at doses ranging from 50 mg to 800 mg per day.


Eligibility criteria: Inclusion Criteria:

* Documented clinical history of chronic hepatitis C and compensated liver disease
* No antiviral treatment for hepatitis C in the 6 months prior to the Screening visit

Other protocol-defined inclusion criteria may apply.

Exclusion Criteria:

* Patient is pregnant or breastfeeding
* Patient is co-infected with HBV or HIV

Other protocol-defined exclusion criteria may apply.

Primary outcomes:
Secondary outcomes:
Other outcomes:
Locations:
city: Pasadena
country: United States
state: California
city: Boston
country: United States
state: Massachusetts
city: Worcester
country: United States
state: Massachusetts
city: Fairfax
country: United States
state: Virginia
Study officials:
References:
Clinical trial NCT05059535: Knee Nerve Cryoneurolysis and Impact on Pain After Prosthetic Surgery
Official title: Cryoneurolysis of the Saphenous Nerve or Geniculate Nerves: Impact on Postoperative Pain and Rehabilitation in Prosthetic Knee Surgery
Study type: INTERVENTIONAL
Overall status: TERMINATED
Phase: PHASE4
Conditions: Knee Injuries
Lead sponsor: GCS Ramsay Santé pour l'Enseignement et la Recherche
Sponsor class: OTHER
Collaborators: name: Euraxi Pharma
First posted: 2021-09-28
Enrollment: 52
Sex: ALL
Minimum age (years): 18
Maximum age (years): 80
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: PARALLEL
Primary purpose: PREVENTION

Brief summary: Interventional, comparative, randomized, controlled study versus standard treatment, in 3 parallel groups, monocentric, aiming to demonstrate the superiority of preoperative cryoneurolysis versus no procedure, in patients operated on for knee arthroplasty and receiving standard analgesia.


Eligibility criteria: Inclusion Criteria:

* Age ≥ 18 years and ≤ 80 years;
* Patient to undergo prosthetic knee surgery;
* Patient in good health (ASA score 1 to 3);
* Patient able to understand the information related to the study, read the information leaflet and agree to sign the consent form.

Exclusion Criteria:

* Known intolerance to any of the products administered during surgery or cryoneurolysis;
* Patient with an electric implant;
* Patient with a contraindication to cryoanalgesia (coagulation disorders, infections, nerve damage);
* Drug addict patient;
* Intervention on septic bone;
* Chronic renal failure (creatinine clearance \<30 mL / min);
* History of cryoglobulinemia, cold urticaria or Raynaud's syndrome;
* Pregnant or breastfeeding woman;
* Patient under guardianship or curatorship, or under a regime of deprivation of liberty;
* Patient participating in another clinical trial, or in a period of exclusion from another clinical trial;
* Patient not beneficiary of a social security scheme.

Primary outcomes:
measure: 90 ° flexion pain 2 days after the arthroscopy
timeFrame: 2 days
Secondary outcomes:
measure: 90 ° flexion pain 1 day after the arthroscopy
timeFrame: 1 day
measure: 90 ° flexion pain 7 days after the arthroscopy
timeFrame: 7 days
measure: 90 ° flexion pain 30 days after the arthroscopy
timeFrame: 30 days
measure: 90 ° flexion pain 90 days after the arthroscopy
timeFrame: 90 days
measure: pain at rest at Day 1
timeFrame: 1 day
measure: pain at rest at Day 2
timeFrame: 2 days
measure: pain at rest at Day 7
timeFrame: 7 days
measure: pain at rest at Day 30
timeFrame: 30 days
measure: pain at rest at Day 90
timeFrame: 90 days
Other outcomes:
Locations:
city: Champigny-sur-marne
country: France
facility: Hôpital privé Paul d'Egine
Study officials:
References:
Clinical trial NCT02150135: Effect of Oncothermia on Improvement of Quality of Life in Unresectable Pancreatic Cancer Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Cancer, Pancreas
Keywords: Pancreatic cancer
Quality of life
Pain
Lead sponsor: Seoul National University Hospital
Sponsor class: OTHER
Collaborators: name: Hospicare Co., Ltd.
First posted: 2014-05-29
Enrollment: 10
Sex: ALL
Minimum age (years): 18
Maximum age (years): 75
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: Patients with pancreatic cancer often suffer from pain. Because of such a pain, their quality of life have seriously deteriorated. There have been a few studies that showed an effect for pain control by hyperthermia (heating the patient's body). However, there are several limitations in conventional hyperthermia. In this study, the investigators tried to show the effect of "Oncothermia" which is more selective to malignant tissue than conventional hyperthermia for pain control, increasing quality of life, and anti-tumor treatment.


Eligibility criteria: Inclusion Criteria:

* Inoperable or recurred pancreatic ductal adenocarcinoma
* After the each cycle of chemotherapy, the disease status was "stable disease"

Exclusion Criteria:

* Person who has an experience of hyperthermia treatment
* Person who has a difficulty of sensing heat
* Person who has a skin graft or breast reconstruction surgery
* Person who has a cardiac pacemaker or an implanted metal
* Pregnant or breast feeding women
* Person with uncontrolled infection, diabetes, hypertension, ischemic heart disease, myocardial infarct within 6 months
* Person who was treated with unproved drugs within 6 months
* Person who have a serious disease which can affect the person's safety
* Person who do not consent to the study

Primary outcomes:
measure: ECOG score change
timeFrame: 3 months after oncothermia treatment
Secondary outcomes:
measure: Progression free survival rate
timeFrame: 3 months later after oncothermia treatment
Other outcomes:
Locations:
city: Seongnam
country: Korea, Republic of
facility: Seoul National University Bundang Hospital
state: Gyeonggi-do
Study officials:
affiliation: Seoul National University Bundang Hospital
name: Jin-Hyeok Hwang, MD PhD
role: PRINCIPAL_INVESTIGATOR
References: